CareDx (CDNA) said Wednesday it completed its previously announced acquisition of Naveris.
Transaction terms were disclosed when the deal was announced in April.
Naveris, a maker of blood-based tests for viral-mediated cancers, will be included in CareDx's consolidated financial results beginning in Q3.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments